vs
Caris Life Sciences, Inc.（CAI）与Guardant Health, Inc.（GH）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是Caris Life Sciences, Inc.的1.3倍（$281.3M vs $216.8M）。Caris Life Sciences, Inc.净利率更高（11.2% vs -45.7%，领先56.9%）。Caris Life Sciences, Inc.同比增速更快（113.4% vs 39.4%）。Caris Life Sciences, Inc.自由现金流更多（$55.3M vs $-54.2M）
Caris生命科学是一家领先的精准医疗生物技术企业，专注于肿瘤领域的先进分子检测服务，为肿瘤医生提供可落地的基因组与分子层面洞察以制定个性化癌症治疗方案，同时与生物制药企业合作加速抗癌新药研发，业务覆盖北美、欧洲及亚太主要市场。
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
CAI vs GH — 直观对比
营收规模更大
GH
是对方的1.3倍
$216.8M
营收增速更快
CAI
高出74.0%
39.4%
净利率更高
CAI
高出56.9%
-45.7%
自由现金流更多
CAI
多$109.6M
$-54.2M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $216.8M | $281.3M |
| 净利润 | $24.3M | $-128.5M |
| 毛利率 | — | 64.6% |
| 营业利润率 | 15.1% | -43.0% |
| 净利率 | 11.2% | -45.7% |
| 营收同比 | 113.4% | 39.4% |
| 净利润同比 | 135.9% | -15.8% |
| 每股收益（稀释后） | $0.08 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CAIGH
| Q4 25 | — | $281.3M | ||
| Q3 25 | $216.8M | $265.2M | ||
| Q2 25 | $181.4M | $232.1M | ||
| Q1 25 | — | $203.5M | ||
| Q4 24 | — | $201.8M | ||
| Q3 24 | $101.6M | $191.5M | ||
| Q2 24 | $100.0M | $177.2M | ||
| Q1 24 | — | $168.5M |
净利润CAIGH
| Q4 25 | — | $-128.5M | ||
| Q3 25 | $24.3M | $-92.7M | ||
| Q2 25 | $-71.8M | $-99.9M | ||
| Q1 25 | — | $-95.2M | ||
| Q4 24 | — | $-111.0M | ||
| Q3 24 | $-67.7M | $-107.8M | ||
| Q2 24 | $-66.2M | $-102.6M | ||
| Q1 24 | — | $-115.0M |
毛利率CAIGH
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | 64.7% | ||
| Q2 25 | — | 65.0% | ||
| Q1 25 | — | 63.3% | ||
| Q4 24 | — | 61.6% | ||
| Q3 24 | — | 61.1% | ||
| Q2 24 | — | 59.1% | ||
| Q1 24 | — | 61.2% |
营业利润率CAIGH
| Q4 25 | — | -43.0% | ||
| Q3 25 | 15.1% | -37.3% | ||
| Q2 25 | -9.9% | -45.9% | ||
| Q1 25 | — | -54.6% | ||
| Q4 24 | — | -62.4% | ||
| Q3 24 | -59.9% | -61.3% | ||
| Q2 24 | -67.0% | -56.8% | ||
| Q1 24 | — | -59.2% |
净利率CAIGH
| Q4 25 | — | -45.7% | ||
| Q3 25 | 11.2% | -35.0% | ||
| Q2 25 | -39.6% | -43.0% | ||
| Q1 25 | — | -46.8% | ||
| Q4 24 | — | -55.0% | ||
| Q3 24 | -66.6% | -56.3% | ||
| Q2 24 | -66.2% | -57.9% | ||
| Q1 24 | — | -68.2% |
每股收益（稀释后）CAIGH
| Q4 25 | — | $-1.01 | ||
| Q3 25 | $0.08 | $-0.74 | ||
| Q2 25 | $-7.97 | $-0.80 | ||
| Q1 25 | — | $-0.77 | ||
| Q4 24 | — | $-0.90 | ||
| Q3 24 | $-2.59 | $-0.88 | ||
| Q2 24 | $-2.54 | $-0.84 | ||
| Q1 24 | — | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $755.5M | $378.2M |
| 总债务越低越好 | $375.9M | $1.5B |
| 股东权益账面价值 | $478.4M | $-99.3M |
| 总资产 | $984.6M | $2.0B |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资CAIGH
| Q4 25 | — | $378.2M | ||
| Q3 25 | $755.5M | $580.0M | ||
| Q2 25 | $721.2M | $629.1M | ||
| Q1 25 | — | $698.6M | ||
| Q4 24 | — | $525.5M | ||
| Q3 24 | — | $585.0M | ||
| Q2 24 | — | $933.7M | ||
| Q1 24 | — | $1.0B |
总债务CAIGH
| Q4 25 | — | $1.5B | ||
| Q3 25 | $375.9M | $1.1B | ||
| Q2 25 | $373.4M | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CAIGH
| Q4 25 | — | $-99.3M | ||
| Q3 25 | $478.4M | $-354.5M | ||
| Q2 25 | $452.9M | $-305.5M | ||
| Q1 25 | — | $-250.8M | ||
| Q4 24 | — | $-139.6M | ||
| Q3 24 | $-2.4B | $-60.1M | ||
| Q2 24 | $-2.4B | $-1.6M | ||
| Q1 24 | — | $68.3M |
总资产CAIGH
| Q4 25 | — | $2.0B | ||
| Q3 25 | $984.6M | $1.3B | ||
| Q2 25 | $955.1M | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.7B |
负债/权益比CAIGH
| Q4 25 | — | — | ||
| Q3 25 | 0.79× | — | ||
| Q2 25 | 0.82× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $62.4M | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | $55.3M | $-54.2M |
| 自由现金流率自由现金流/营收 | 25.5% | -19.3% |
| 资本支出强度资本支出/营收 | 3.3% | 9.9% |
| 现金转化率经营现金流/净利润 | 2.57× | — |
| 过去12个月自由现金流最近4个季度 | — | $-233.1M |
8季度趋势，按日历期对齐
经营现金流CAIGH
| Q4 25 | — | $-26.4M | ||
| Q3 25 | $62.4M | $-35.4M | ||
| Q2 25 | — | $-60.3M | ||
| Q1 25 | — | $-62.7M | ||
| Q4 24 | — | $-64.5M | ||
| Q3 24 | — | $-51.1M | ||
| Q2 24 | — | $-94.0M | ||
| Q1 24 | — | $-30.3M |
自由现金流CAIGH
| Q4 25 | — | $-54.2M | ||
| Q3 25 | $55.3M | $-45.8M | ||
| Q2 25 | — | $-65.9M | ||
| Q1 25 | — | $-67.1M | ||
| Q4 24 | — | $-83.4M | ||
| Q3 24 | — | $-55.3M | ||
| Q2 24 | — | $-99.1M | ||
| Q1 24 | — | $-37.2M |
自由现金流率CAIGH
| Q4 25 | — | -19.3% | ||
| Q3 25 | 25.5% | -17.3% | ||
| Q2 25 | — | -28.4% | ||
| Q1 25 | — | -33.0% | ||
| Q4 24 | — | -41.3% | ||
| Q3 24 | — | -28.9% | ||
| Q2 24 | — | -55.9% | ||
| Q1 24 | — | -22.1% |
资本支出强度CAIGH
| Q4 25 | — | 9.9% | ||
| Q3 25 | 3.3% | 3.9% | ||
| Q2 25 | — | 2.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.4% | ||
| Q3 24 | — | 2.2% | ||
| Q2 24 | — | 2.9% | ||
| Q1 24 | — | 4.1% |
现金转化率CAIGH
| Q4 25 | — | — | ||
| Q3 25 | 2.57× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAI
| Molecular Profiling Services | $207.6M | 96% |
| Pharma Research And Development Services | $9.2M | 4% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
